CliffBio
small molecule

DEXTROAMPHETAMINE SULFATE

DEXTROAMPHETAMINE SULFATE

Loss of exclusivity—loss of exclusivity
CompanyTris. →See this company's full patent-cliff portfolio

Drug detail

Brand nameDEXTROAMPHETAMINE SULFATE
Active ingredientDEXTROAMPHETAMINE SULFATE
Strength10MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2022
Marketing statusDISCN

More from Tris.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DEXTROAMPHETAMINE SULFATE patent cliff — loss of exclusivity — | CliffBio